Invasive fungal infections in hematologic diseases: evidence, challenges, and clinical practice

Area of Science:

• Hematology
• Mycology
• Infectious Diseases

Background:

• Patients with acute leukemia, especially those undergoing allogeneic hematopoietic stem cell transplantation, are highly susceptible to invasive fungal infections (IFIs).
• IFIs significantly contribute to increased morbidity and mortality in this vulnerable patient population.
• Recent advancements in antifungal therapies have improved survival rates for patients with hematologic malignancies.

Purpose of the Study:

• To review the evolving landscape of invasive fungal infection management in acute leukemia patients.
• To highlight emerging challenges such as breakthrough infections, rare fungal pathogens, and azole resistance.
• To emphasize the need for advanced diagnostic tools and a deeper understanding of host immunity.

Main Methods:

• Literature review of recent advancements in antifungal prophylaxis and treatment strategies.
• Analysis of trends in IFI epidemiology, including the emergence of uncommon fungi and resistance patterns.
• Discussion of novel diagnostic biomarkers and antifungal susceptibility testing integration.

Main Results:

• Despite prophylaxis, breakthrough IFIs are increasing, alongside infections from rare fungi and growing azole resistance.
• Aspergillus species remain common, but non-Aspergillus molds and yeasts are increasingly identified.
• Current diagnostic methods like galactomannan testing may be insufficient, requiring novel biomarkers.

Conclusions:

• Optimized IFI management requires individualized care, multidisciplinary collaboration, and integration of novel diagnostic tools.
• Understanding host immunity is crucial for developing next-generation IFI management strategies.
• Continued research into prevention, diagnosis, and treatment is essential to improve outcomes for acute leukemia patients at high risk for IFIs.